National Heart Institute Study Shows No Significant Benefit of Convalescent Plasma for COVID-19 Outpatients With Early Symptoms
August 19, 2021
August 19, 2021
BETHESDA, Maryland, Aug. 19 (TNSJou) -- The National Institutes of Health's National Heart, Lung and Blood Institute issued the following news release:
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in February 2021 due t . . .
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in February 2021 due t . . .